
As we celebrate National Recovery Month, read insights from a survey of people living with AUD.
Craig Hopkinson reflects on Alkermes' efforts to leverage our deep neuroscience expertise to make a difference.


Learn about the impact of the Pathways Research Awards program.
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.